This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
dermatomyositis
Dermatomyositis
Dermatomyositis is an immune-mediated myopathy with pathognomonic skin findings (heliotrope, Gottron's); type I IFN signature is central; MSAs (anti-MDA5, anti-TIF1γ, anti-NXP2, anti-Jo-1) stratify subtypes; IVIG (FDA Oct 2021), JAK inhibitors (baricitinib) are treatments.
Entry Metadata
| Field | Value |
|---|---|
| ID | dermatomyositis |
| Name | Dermatomyositis |
| Status | draft |
| Last reviewed | 2026-06-07 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(12):2271-2282. · PubMed 29106061
- Aggarwal R, Charles-Schoeman C, Schessl J, et al. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med. 2022;387(14):1264-1278. · PubMed 36198072
- Sato S, Kuwana M. Clinicopathological features of Japanese patients with anti-CADM-140/MDA5 antibody-positive dermatomyositis. Arthritis Rheum. 2009;61(5):611-620. · PubMed 19405014
- Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292(7):344-347. · PubMed 1090839